## 2-(1H-imidazol-1-yl)-5-(trifluoromethyl)pyridine: A versatile building block for pharmaceuticals and materials
**2-(1H-imidazol-1-yl)-5-(trifluoromethyl)pyridine** is a heterocyclic compound that combines a pyridine ring with an imidazole ring and a trifluoromethyl group. This seemingly complex molecule holds significant potential for research due to its versatility and unique properties.
**Here's why it's important:**
* **Pharmaceutical potential:**
* **Ligand for receptor binding:** The imidazole ring, often found in pharmaceuticals, makes it an ideal candidate for binding to various receptors. This opens doors for its use in developing new drugs targeting specific pathways or diseases.
* **Metabolic stability:** The trifluoromethyl group significantly enhances metabolic stability, allowing the compound to last longer in the body and potentially leading to more potent and longer-lasting therapeutic effects.
* **Diverse chemical reactivity:** The presence of both nitrogen atoms and a pyridine ring offers opportunities for further chemical modifications, creating a diverse range of derivatives with potentially distinct biological activities.
* **Materials science applications:**
* **Fluorescent properties:** The trifluoromethyl group can act as a fluorophore, emitting light under certain conditions. This opens possibilities for using this compound as a fluorescent probe in various applications like imaging or sensing.
* **Electronic properties:** The pyridine ring and the imidazole ring contribute to specific electronic properties, making it potentially useful in developing new organic electronics, like solar cells or organic light-emitting diodes (OLEDs).
* **Polymers:** The compound can be incorporated into polymers, potentially modifying their properties like conductivity, thermal stability, or mechanical strength.
**Research areas of interest:**
* **Drug discovery:** Exploring the potential of 2-(1H-imidazol-1-yl)-5-(trifluoromethyl)pyridine as a lead compound for new drugs against various diseases like cancer, infections, or neurological disorders.
* **Materials development:** Investigating its potential as a building block for fluorescent probes, organic electronics, and advanced materials.
* **Chemical synthesis:** Developing efficient and scalable synthetic methods for producing this compound and its derivatives.
**In summary, 2-(1H-imidazol-1-yl)-5-(trifluoromethyl)pyridine is a promising molecule with high potential for research in various fields, especially pharmaceuticals and materials science. Its unique combination of functionalities opens doors for developing novel applications in the future.**
ID Source | ID |
---|---|
PubMed CID | 737967 |
CHEMBL ID | 2143495 |
CHEBI ID | 194837 |
Synonym |
---|
smr000062453 |
MLS000096537 , |
MAYBRIDGE1_004785 |
SR-01000618075-2 |
HMS555B11 |
2-imidazol-1-yl-5-(trifluoromethyl)pyridine |
2-imidazol-1-yl-5-(triluoromethyl)pyridine |
2-(1h-imidazol-1-yl)-5-(trifluoromethyl)pyridine |
CHEBI:194837 |
AKOS001041091 |
HMS2343B03 |
CCG-43505 |
8B-017 |
339020-58-5 |
CHEMBL2143495 |
2-(1h-imidazol-1-yl)-5-(trifluoromethyl)pyridine, aldrichcpr |
Z55183723 |
mfcd00243667 |
BRD-K39321947-001-08-9 |
behwgluheguqrd-uhfffaoysa-n |
Class | Description |
---|---|
pyridines | Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
glp-1 receptor, partial | Homo sapiens (human) | Potency | 0.5012 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 5 (62.50) | 24.3611 |
2020's | 2 (25.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.17) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |